Core Viewpoint - Credit Lyonnais has raised JD Health's (06618) adjusted net profit forecasts for the fiscal years 2026 and 2027 by 1% and 2% respectively, reflecting the recovery in drug sales and profit expansion prospects, while maintaining an "Outperform" rating and a target price of HKD 71 [1] Group 1: Financial Performance - JD Health is expected to maintain growth momentum in the second half of last year, driven by strong performance during the Double Eleven sales event and a surge in flu cases in December, with revenue projected to increase by 24.5% year-on-year to RMB 37.1 billion [1] - The company is anticipated to see adjusted EBIT double year-on-year to RMB 2.1 billion, supported by gross margin expansion and operational leverage [1] - Revenue for 2026 is expected to grow by 16% year-on-year [1]

京东健康受双十一销售表现良好及12月流感感染个案激增所推动，预计去年下半年可保持增长势头，收 入同比升24.5%至371亿元人民币。该行续预期，受毛利率扩张与营运杠杆支撑，经调整EBIT或同比翻 倍至21亿元人民币，并预计公司2026年收入将同比增长16%。 智通财经APP获悉，里昂发布研报称，上调京东健康(06618)2026及2027财年经调整净利润预测1%及 2%，以反映药物销售复苏及利润扩张前景，重申"跑赢大市"评级，续予目标价71港元。 ...

Core Viewpoint - The report from Citi indicates that JD Health is expected to maintain growth momentum in the second half of last year, driven by strong performance during the Double Eleven sales event and a surge in flu cases in December [1] Financial Performance - Revenue is projected to increase by 24.5% year-on-year to 37.1 billion yuan [1] - Adjusted EBIT is expected to double year-on-year to 2.1 billion yuan, supported by margin expansion and operational leverage [1] Profit Forecast - Citi has raised JD Health's adjusted net profit forecasts for the fiscal years 2026 and 2027 by 1% and 2% respectively, reflecting the recovery in drug sales and profit expansion prospects [1] - The firm maintains a "Outperform" rating and sets a target price of 71 HKD for JD Health [1]

Core Viewpoint - The recent approval of a pilot program for internet-based first consultations in pediatric healthcare by the National Health Commission has sparked enthusiasm in the industry, marking a significant step towards expanding the scope of internet healthcare services [1][5]. Group 1: Pilot Program Details - The pilot program will be conducted at Beijing Children's Hospital and Capital Institute of Pediatrics, focusing on three specialties: child growth and development, child nutrition, and pediatric skin diseases, running from January to December 2026 [1][2]. - The selection of medical institutions for the pilot was based on a comprehensive evaluation of their management capabilities, operational experience, and the expertise of their medical teams [2]. - The pilot aims to allow doctors to conduct initial diagnoses online and prescribe medications, representing a breakthrough in the internet healthcare model while ensuring safety and quality [2]. Group 2: Initial Operations and Demand - Initial operations of the pilot program have shown high accessibility for patients, who can book appointments through designated online platforms [3]. - As of February 3, 2023, the appointment availability for pediatric dermatology was fully booked for the day, indicating strong demand, while other specialties had varying levels of availability [4]. Group 3: Industry Implications - The pilot program serves as a small-scale test to accumulate experience and validate the model, with limited immediate impact on internet healthcare companies [5]. - It signals a potential expansion of first consultation services in the future, providing confidence for long-term industry development [5]. Group 4: Opportunities for Internet Healthcare Platforms - The pilot program offers valuable insights for internet healthcare platforms regarding specialty demands, particularly in pediatric growth, nutrition, and dermatology, which are areas of high cross-regional medical needs [7]. - The program may enhance public trust in online healthcare services, potentially increasing the overall penetration rate of internet healthcare [8]. - The pilot could attract new patients who have not previously engaged with internet healthcare, thus providing a new growth opportunity for the industry [9]. Group 5: Strategic Considerations for Third-Party Platforms - As the pilot progresses, third-party platforms must consider their positioning, especially if top-tier hospitals begin to normalize internet first consultations [10][11]. - The distribution of quality medical resources remains uneven, with major hospitals still playing a crucial role in providing high-quality care [10]. - Third-party platforms should focus on collaboration with physical hospitals to enhance their value proposition and develop integrated healthcare solutions [12]. Group 6: Industry Challenges and Future Outlook - The industry must remain vigilant against practices that undermine the integrity of online consultations, such as the rapid issuance of prescriptions without thorough evaluations [13]. - The pilot program opens new possibilities for the future of internet healthcare, emphasizing the need for platforms to prioritize the essence of medical care over short-term gains [13].

Core Viewpoint - Ark Health (06086) has successfully completed a placement and subscription of shares, raising approximately HKD 144.3 million for the development of its AI-driven chronic disease management platform [1] Group 1: Share Placement and Subscription - The placement of a total of 45.181 million shares was completed at a price of HKD 3.32 per share, with shares allocated to no fewer than six subscribers [1] - The subscription was finalized on February 2, 2026, with the same number of shares issued at the same price, representing approximately 3.26% of the company's enlarged issued share capital [1] Group 2: Use of Proceeds - Approximately 90% of the net proceeds will be allocated to accelerate the development of the AI-driven chronic disease management platform, including model development, infrastructure expansion, talent acquisition, data collection, and the launch of AI-enhanced services [1] - The remaining 10% of the proceeds will be used for working capital and other general corporate purposes [1]

Core Viewpoint - The National Health Commission has approved a one-year pilot program for online first consultations in Beijing, focusing on pediatric specialties to enhance healthcare accessibility and efficiency for patients, especially those from outside the capital [1][5][8]. Group 1: Pilot Program Details - The pilot program will run from January to December 2026, utilizing online platforms for initial consultations in pediatric growth, nutrition, and skin disease specialties [1][5]. - The initiative aims to alleviate the burden on Beijing's healthcare system by allowing patients from remote areas to access top pediatric specialists without long-distance travel [5][8]. Group 2: Market Implications - The pilot is expected to increase online prescription sales, as it allows for initial diagnoses without the need for follow-up visits [5][9]. - Experts suggest that while the pilot focuses on low-risk conditions suitable for online diagnosis, the broader market impact may be limited, as many conditions still require in-person examinations [5][9]. Group 3: Regulatory Framework - The pilot will enforce strict qualifications for physicians conducting online consultations, requiring at least three years of clinical experience and a minimum of one year in online follow-up care [9][11]. - A quality monitoring and patient rights protection mechanism will be established to ensure safety and compliance during the pilot [9][11]. Group 4: Future Prospects - The pilot is part of a broader trend towards integrating online consultations into the healthcare system, with potential for expansion to other specialties and conditions in the future [6][10]. - Research indicates that certain mild conditions can be effectively managed online, suggesting a pathway for developing differentiated online consultation services based on disease types [10][11].

Core Viewpoint - The launch of online first consultation services by Beijing Children's Hospital and Capital Institute of Pediatrics marks a significant step in enhancing access to quality medical care through internet-based healthcare solutions [1][3]. Group 1: Online First Consultation Services - Starting from January 2026, Beijing will initiate a one-year pilot program for online first consultations, allowing patients to book appointments in three specialized areas: pediatric growth and development, pediatric nutrition, and pediatric skin diseases [1][3]. - The pilot aims to expand internet consultations beyond common and chronic diseases, which previously required in-person visit records for follow-up [1][3]. Group 2: Rationale for Selection - The selection of these two hospitals and three specialties is based on the concentration of quality medical resources in Beijing, the hospitals' management capabilities, and the volume of out-of-town patients [3][4]. - The chosen specialties are deemed suitable for online consultations due to the relatively stable conditions of patients and the reliance on visual information for diagnosis [3][4]. Group 3: Quality and Safety Measures - The pilot program emphasizes high standards for physicians, requiring them to have at least three years of independent clinical experience and specific qualifications [4]. - The process includes safeguards such as ensuring a guardian is present during consultations and utilizing a regulatory platform for monitoring [4]. Group 4: Broader Implications for Healthcare - The pilot is expected to catalyze the integration of internet healthcare services, potentially transforming the "internet + healthcare" ecosystem [5]. - Recommendations include developing electronic prescription platforms and exploring insurance coverage for online consultations to enhance accessibility [5][6]. - The initiative may also drive innovation in medical technology, including telemedicine and AI-assisted diagnostics [5][6].

Investment Rating - The report does not explicitly provide an investment rating for the industry or specific companies involved in the internet-based first consultation pilot in Beijing. Core Insights - The pilot program for internet-based first consultations in Beijing is expected to have landmark significance for nationwide policy expansion, aiming to relieve offline clinical pressure and extend quality medical resources digitally across China [2][6]. - The policy is anticipated to drive online traffic growth and accelerate prescription outflow, particularly in specialties suitable for remote diagnosis such as dermatology, mental health, and nutrition [7][8]. - The integration of "consultation-examination-diagnosis-medication" services is facilitated by this policy, potentially streamlining patient journeys and reducing transportation costs [8]. Summary by Sections Event - On January 31, 2026, the National Health Commission approved a pilot for internet-based first consultations in pediatric specialties in Beijing, running from January to December 2026 [1][5]. Commentary - The pilot aims to address the medical needs of out-of-town patients and relieve non-capital functions in Beijing, with the potential to serve as a reference for similar initiatives nationwide [2][6]. - If the scope of internet-based first consultations expands, it could lead to significant growth in online consultations and related health product sales [7]. - Leading companies like Alibaba Health and JD Health are expected to benefit from the expansion of this policy [8].

Core Viewpoint - The launch of online first consultation services in pediatric specialties by Beijing Children's Hospital and Capital Institute of Pediatrics marks a significant step in enhancing quality medical services through internet healthcare, starting a one-year pilot program in 2026 [1][2]. Group 1: Online First Consultation Services - The pilot program allows patients to book online first consultations in three pediatric specialties, which were chosen based on the concentration of quality medical resources and patient demand [1][2]. - The initiative aims to transition from online follow-up consultations to first consultations, expanding the scope of internet healthcare services [1]. Group 2: Safety and Quality Assurance - High standards for physicians are mandated, requiring at least three years of independent clinical experience and specific qualifications to ensure quality in online consultations [2]. - The process includes strict monitoring and traceability of medical activities, ensuring that consultations are conducted safely and appropriately [2]. Group 3: Integration of Healthcare Services - The realization of online prescription rights is seen as crucial for fully integrating internet healthcare services, which could enhance convenience for patients [3]. - Recommendations include developing electronic prescription platforms and exploring insurance coverage for online first consultations to facilitate broader access [3]. Group 4: Future Prospects - The pilot program is expected to catalyze innovations in medical technology, including telemedicine and AI-assisted diagnostics, as it progresses [3]. - With supportive policies, the scope of internet healthcare services may expand to include chronic disease management and mental health consultations, aiming to improve patient access and reduce the need for physical visits [3].

Investment Rating - The report maintains an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, while China National Pharmaceutical Group is rated "Neutral" [1]. Core Insights - The Hong Kong healthcare sector experienced a broad-based correction due to capital pressures, with pharmaceutical distribution remaining relatively stable [4][28]. - The Hang Seng Healthcare Index fell by 3.0% this week, underperforming the Hang Seng Index by 5.4 percentage points, but has gained 8.6% year-to-date, outperforming the Hang Seng Index by 1.7 percentage points [14][27]. - The top five gainers in the sector included Leads Biolabs-B (+19.3%), Sihuan Pharmaceutical (+17.9%), and Tigermed (+7.6%), while the bottom five decliners included Medlive Technology (-16.2%) and Laekna-B (-14.1%) [4][29]. Summary by Sections Market Performance - The report indicates that various sub-sectors within the Hong Kong healthcare market experienced declines, with pharmaceutical distribution down by 0.3%, internet healthcare down by 2.1%, and medical devices down by 5.0% [4][28]. Company Highlights - Rongchang Biopharmaceutical announced a revenue forecast of 3.25 billion yuan for 2025, representing an 89% year-on-year increase, and reported a turnaround to profitability [11]. - A collaboration agreement was signed between CSPC Pharmaceutical and AstraZeneca, involving a total payment of $18.5 billion for the licensing of GLP-1 long-acting assets [11]. - AstraZeneca plans to invest $15 billion in China by 2030, focusing on expanding drug manufacturing and R&D capabilities [12]. - Kangzheng Pharmaceutical's lebrikizumab cream has been approved for the treatment of non-segmental vitiligo in patients aged 12 and older [12]. Regulatory Developments - The National Health Commission approved a pilot program for internet-based first consultations in Beijing, which is expected to accelerate prescription outflow and improve access to healthcare services [13].